News
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
One of Wall Street's biggest bulls sees tech powering an 11% gain in stocks through the rest of 2025
Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...
Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...
Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...
7d
Barchart on MSNThis Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...
7d
Barchart on MSNRetirement Ready: 3 Dividend Stocks to Set and ForgetA retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...
But analysts aren’t convinced a turnaround is coming anytime soon, making the stock’s lofty valuation look more like a gamble than a safe bet. In short, while Pfizer’s stock has been the life of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results